BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
55.05
-0.12 (-0.22%)
Jun 30, 2025, 10:30 AM - Market open
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
The 22 analysts that cover BioMarin Pharmaceutical stock have a consensus rating of "Buy" and an average price target of $93.43, which forecasts a 69.72% increase in the stock price over the next year. The lowest target is $65 and the highest is $126.
Price Target: $93.43 (+69.72%)
Analyst Consensus: Buy
* Price targets were last updated on May 5, 2025.
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 6 | 6 |
| Buy | 10 | 11 | 11 | 11 | 10 | 10 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 22 | 22 | 22 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $124 → $104 | Strong Buy | Maintains | $124 → $104 | +88.92% | May 5, 2025 |
| Citigroup | Citigroup | Hold Maintains $82 → $78 | Hold | Maintains | $82 → $78 | +41.69% | May 2, 2025 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $98 | Hold → Buy | Upgrades | $98 | +78.02% | Feb 24, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $78 → $80 | Hold | Maintains | $78 → $80 | +45.32% | Feb 20, 2025 |
| Citigroup | Citigroup | Hold Maintains $81 → $82 | Hold | Maintains | $81 → $82 | +48.96% | Feb 20, 2025 |
Financial Forecast
Revenue This Year
3.20B
from 2.85B
Increased by 12.23%
Revenue Next Year
3.52B
from 3.20B
Increased by 9.99%
EPS This Year
3.52
from 2.21
Increased by 59.69%
EPS Next Year
4.40
from 3.52
Increased by 24.84%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.4B | 3.9B | 4.3B | ||
| Avg | 3.2B | 3.5B | 3.8B | ||
| Low | 3.0B | 3.1B | 3.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 17.7% | 21.4% | 23.3% | ||
| Avg | 12.2% | 10.0% | 8.5% | ||
| Low | 6.1% | -2.2% | -7.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.11 | 5.42 | 6.79 | ||
| Avg | 3.52 | 4.40 | 5.24 | ||
| Low | 2.49 | 2.97 | 3.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 86.4% | 53.7% | 54.4% | ||
| Avg | 59.7% | 24.8% | 19.2% | ||
| Low | 12.8% | -15.8% | -19.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.